Table 1: Characteristics of the Patients at Baseline

Characteristic

Treatment

 

Group 1 Standard of care + tocilizumab (n = 54)

Group 2 Standard of care + tocilizumab + remdesivir (n = 73)

P value

Average Age - median (IQR)

63 (54.65)

65 (52.65)

0.0008

Ethnicity - No. (%)

   

0.2

White or Caucasian

3 (5)

10 (14)

 

Hispanic or Latino

46 (85)

51 (70)

 

African American

4 (7)

7 (10)

 

Other

1 (2)

5 (7)

 

Sex -No. (%)

   

0.3

Male

29 (54)

46 (63)

 

Female

25 (46)

27 (37)

 

Respiratory support received - No. (%)

   

< 0.0001

Category 1

35 (65)

14 (19)

 

Category 2

12 (22)

39 (53)

 

Category 3

7 (13)

20 (27)

 

Previous coexisting disease - No. (%)

     

Obesity

25 (46)

44 (61)

0.2

Diabetes

16 (30)

29 (40)

0.24

COPD

3 (6)

7 (10)

0.5

CVD§

29 (54)

55 (75)

0.01

Reduced kidney function

24 (44)

26 (36)

0.3

Current smoker - No. (%)

1 (2)

10 (14)

0.02

Category 1: Nasal cannula, humidified nasal oxygen, simple face mask; Category 2: High flow, non-rebreather, BIPAP, CPAP; Category 3: ECMO, mechanical ventilation, PRVC/AC, APRV, assistance/control. When tested via Chi-square, group 2 has significantly more patients receiving higher levels of respiratory support (p < 0.0001); Obesity was defined as a body mass index of 30 or greater; §Cardiovascular disease included heart failure, stroke, myocardial Infarction, peripheral artery disease, coronary artery disease, hyperlipidemia or hypertension; Reduced kidney function was defined as an estimated glomerular filtration rate of less than 60 ml per minute per 1.73 m2.